Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
EPANOVA vs TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Travasol 2.75% in Dextrose 15% is a parenteral nutrition solution. Travassol provides amino acids for protein synthesis, while dextrose provides caloric energy. The mechanism involves intravenous administration to bypass gastrointestinal absorption, directly delivering substrates for metabolism and tissue repair.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion: 1000-2000 mL/day (providing 27.5 g amino acids and 150 g dextrose) at a rate not exceeding 4 mL/kg/hour.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Not applicable as a direct drug; components have variable half-lives: amino acids are rapidly cleared (minutes to hours), dextrose is regulated by insulin (glucose half-life ~1-2 hours in euglycemia).
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Travasol 2.75% in dextrose 15% is a parenteral nutrition solution. The amino acids are metabolized and their nitrogen is primarily excreted as urea in urine (renal >90%), with minimal biliary or fecal elimination. Dextrose is metabolized to CO2 and water, exhaled via lungs and excreted renally.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution